Peptides DB

Research-centric peptide and protocol reference hub

AOD-9604 vs Semaglutide: Why They're Not Comparable

AOD-9604 and Semaglutide both appear in 'fat-loss peptide' conversations but they're not comparable interventions. Semaglutide is FDA-approved with ~15% trial weight loss; AOD-9604 has weak human evidence and minimal trial effect.

By PeptidesDB EditorialPublished Jun 18, 20264 min read

AOD-9604 and Semaglutide both appear in "fat-loss peptide" conversations but they are not comparable interventions. Semaglutide is an FDA-approved GLP-1 receptor agonist with ~15% mean weight loss at 68 weeks in trials. AOD-9604 is a fragment of growth hormone (residues 176-191) marketed for fat loss; the human-trial evidence supports minimal or no weight-loss effect at safe doses. This article covers what each is, why they're not interchangeable, and where AOD-9604 might (or might not) have a real role.

For the broader frame see peptides for weight loss and best peptides for fat loss.

Quick verdict table

AOD-9604 Semaglutide
What it is hGH fragment 176-191 GLP-1 receptor agonist
Mechanism (claimed) Mimic GH's fat-mobilization without GH's other effects Slow gastric emptying, suppress appetite, glucose-dependent insulin release
FDA approval None (failed development for obesity) Approved 2017 (T2D), 2021 (obesity)
Best published human weight-loss effect Trivial in published trials ~15% at 68 weeks (STEP-1)
Side effects Generally mild GI-dominated, dose-related
Cost (research-use) $50–$200/month $900–$1,400/month brand
Practical role Speculative addition; minimal evidence Foundational weight-loss tool

What each one actually is

AOD-9604

A 16-amino-acid synthetic peptide corresponding to residues 176-191 of human growth hormone. The hypothesis: this region of GH retains the fat-mobilizing effect of the full hormone without GH's other systemic effects (IGF-1 elevation, water retention, joint discomfort, etc.).

The compound went through clinical development by Metabolic Pharmaceuticals in the 2000s as an obesity treatment. The pivotal trials showed weight loss in the AOD-9604 arms that was statistically significant in some subgroups but not clinically meaningful compared with placebo (~1–2% over 24 weeks). Development for obesity was discontinued.

AOD-9604 research profile.

Semaglutide

A long-acting GLP-1 receptor agonist. The mechanism is well-characterized: appetite suppression, slowed gastric emptying, glucose-dependent insulin release. The STEP clinical-trial program established ~15% mean weight loss at 68 weeks in non-diabetic obesity; the SELECT trial established 20% relative MACE reduction. FDA-approved as Ozempic (T2D) and Wegovy (obesity).

Semaglutide research profile.

Why they're not comparable

  • Mechanism class. GLP-1 receptor agonism is a robust, multiply-confirmed mechanism for appetite suppression and weight loss. GH-fragment "fat mobilization" was a hypothesis that didn't deliver clinically meaningful effect in development trials.
  • Evidence quality. Semaglutide has Phase 3 data in tens of thousands of patients. AOD-9604 has small Phase 2 data that didn't meet primary endpoints for obesity.
  • Effect size. ~15% vs ~1–2% at maintenance trial timepoints.
  • Regulatory status. Approved drug vs research-use compound that failed obesity development.

When (if ever) AOD-9604 has a role

The honest answer: at most a speculative supportive role. The places it shows up in protocols:

  • Combined with caloric restriction as a "fat-burner" addition. There's no published evidence the addition produces measurable weight loss beyond what caloric restriction produces alone.
  • As an adjunct to GH-axis peptides (Ipamorelin / CJC-1295 / MK-677) for body-composition focus. Adds cost; doesn't add evidence-supported effect.
  • As a "less-systemic" alternative to HGH for users who want fat-mobilization effects without the GH side-effect profile. The evidence doesn't support this trade-off — you're trading real GH effects (which include real risks) for minimal AOD-9604 effect.

None of these have published evidence behind them. The realistic frame is that AOD-9604 is, at the doses typically used, near-placebo.

What about combining AOD-9604 with Semaglutide?

Some research-chemical protocols add AOD-9604 to a GLP-1. There is no clinical evidence that this combination produces more weight loss than Semaglutide alone. The cost adds; the side-effect surface adds (mildly); the measurable benefit does not.

If you want to add a complementary-mechanism peptide on top of Semaglutide, the evidence-supported options are:

  • Cagrilintide — different mechanism (amylin), Phase 3 data on the combination (CagriSema).
  • Tesamorelin — GHRH analog, specifically targets visceral fat reduction; FDA-approved for HIV lipodystrophy.

Both have real published rationale. AOD-9604 does not.

What about Tesamorelin instead?

Tesamorelin is FDA-approved as a GHRH analog for visceral fat reduction in HIV-associated lipodystrophy. The on-label evidence is specifically visceral adipose tissue reduction (not whole-body weight loss). Off-label use for body-composition purposes is widespread; clinical evidence outside the lipodystrophy indication is weaker than the on-label evidence but is meaningful.

For users specifically looking for a peptide-class addition to GLP-1 therapy for body-composition reasons, Tesamorelin is a more defensible option than AOD-9604.

Tesamorelin research profile.

Bottom line

  • Semaglutide is the foundational tool. AOD-9604 is largely a placebo for weight loss at safe doses.
  • They are not equivalent and shouldn't be compared as alternatives.
  • If you're building a stack: GLP-1 + Cagrilintide (CagriSema) or GLP-1 + Tesamorelin are the evidence-supported pairings, not GLP-1 + AOD-9604.

Where to go from here